<DOC>
	<DOCNO>NCT00976820</DOCNO>
	<brief_summary>The purpose study characterize safety immune response H1N1 ( swine ) flu vaccine GSK2340274A GSK2340273A child 6 month le 9 year age . This Protocol Posting update follow Protocol amendment 1 &amp; 2 , September October 2009 . The section impact study design , objectives analysis method .</brief_summary>
	<brief_title>Safety Immunogenicity H1N1 Vaccines Children Aged 6 Months Less Than 9 Years Age</brief_title>
	<detailed_description>Collaborators : United States Department Health Human Services , Office Biomedical Advanced Research Development Authority</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female child 6 month le 9 year age time first vaccination . Written inform consent obtain subject 's parent/ legally acceptable representative ( LAR ) ; write informed assent obtain subject appropriate . Good general health establish medical history clinical examination enter study . Safety laboratory test result within parameter specify protocol . Parent/ LAR access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device . Subjects investigator believe parent ( ) / LAR comply requirement protocol . Female subject nonchildbearing potential ( premenarche ) may enrol study . Previous vaccination H1N1vlike virus vaccine medical history physicianconfirmed infection H1N1vlike virus . Presence evidence substance abuse neurological psychiatric diagnosis , even stable , deemed investigator render potential subject parent ( ) / LAR ( ) unable/unlikely provide accurate safety report . Presence temperature &gt; = 38.0ºC ( &gt; =100.4ºF ) route method , acute symptom great `` mild '' severity schedule date first vaccination . Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination Receipt systemic glucocorticoid within 1 month prior study enrollment , cytotoxic immunosuppressive drug within 6 month study enrollment . Topical , intraarticular inhale glucocorticoid allow . Receipt immunoglobulins and/or blood product within 3 month study enrollment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin eligible dos give 24 hour study vaccination . Persons receive prophylactic antiplatelet medication , e.g. , lowdose acetylsalicylic acid , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome within 6 week receipt seasonal influenza vaccine . Administration license vaccine within 4 week first dose study vaccine , exception seasonal influenza vaccine . Planned administration vaccine foreseen study protocol Day 0 Day 42 phlebotomy , include seasonal influenza vaccine . Routine childhood vaccination exempt delayed , must administer day H1N1 vaccine candidate . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Any known suspected allergy constituent influenza vaccine history anaphylactictype reaction constituent influenza vaccine ; history severe adverse reaction previous influenza vaccine . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>influenza infection</keyword>
	<keyword>Influenza Vaccines</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK2340273A</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK2340274A</keyword>
</DOC>